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We present the in vitro expression and purification of N-terminal fragments of human perlecan in 
insect cells. Three tailored fragments of human perlecan cDNA were introduced into the polyhedrin locus 
of baculovirus expression vectors (BEVs) encoding amino acids 1 — 196 (domain I), 1-404 (domain 
1 + 11“) and 1 —506 (domain I+IIilb). The integrity of the BEVs was checked by DNA sequencing, polymer­
ase chain reaction, restriction enzyme analysis and Southern blotting. Northern hybridization and meta­
bolic labeling with [/^SJmethionine showed that expression of the perlecan-(l —404)- and the -(1—506)- 
peptide was successful, but in the case of die perlecan-(l — 196)-peptide no recombinant protein was 
produced, lmmunoblotting showed that both the (1—404)-peptide and (1 —506)-peptide are recognized 
by 95J 10, a monoclonal antibody that was previously raised against perlecan-(24—404)-peptide expressed 
in Escherichia coli, Gel permeation and anion-exchange chromatography were applied to purify the re­
combinant proteins. Glyeosaminoglycans were demonstrated to be present. Deglycosylation with chon- 
droitinase ABC showed that the perlecan-(l —404)-peptide was glycosylated with chondroitin sulfate 
residues. Consistent with these results, glyeosaminoglycans isolated from the perlecan-(l —404)-peptide 
were identified as chondroitin sulfate by agarose gel electrophoresis. Furthermore the perlecan-( 1—404)- 
peptide showed affinity to immobilized basic fibroblast growth factor. The availability of baculovirus- 
derived recombinant perlecan fragments will facilitate domain-specific investigation of the structural and 
functional properties of perlecan in the future.
Keywords; perlecan; structure; baculovirus expression; chondroitin sulfate; basic fibroblast-growth 
factor.
Heparan sulfate proteoglycans are essential components of 
cell surface and basement membranes serving a diversity of 
(unctions. Perlecan (HSPG2) is a large proteoglycan of base­
ment membranes consisting of a 467-kDa core protein with three 
heparan sulfate chains attached lo its N-terminal domain. The 
other domains share similarity with the low-density lipoprotein 
receptor (domain II), laminin « 1,//1 and yl short arms (domain 
III), neural cel I-adhesion molecule {domain IV) and the globular 
end of laminin «1 (domain V) | l - 3 ] .  The perlecan gene is 
mapped to the short arm of chromosome 1 and comprises over 
120 kb, consisting of 94 exons |4, 5]. Consistent with its multi­
domain structure, the core protein of perlecan serves multiple 
functions, The proteoglycan is anchored within the basement 
membrane through binding to laminins (an interaction that is 
enhanced in presence of nidogen/entaetin), fibronectin and colla-
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Ahhreviafittns. AcNPV, Auiographci callfornica  nuclear polyhedrosis 
virus; HHV, baculovirus expression vector; bFGF, basic fibroblast 
growth factor; GBM, glomerular basement membrane; HSPG, heparan
sulfate proteoglycan.
Iw zvm vs. Peroxidase (EC 1.11.1.7); polynucleotidc kinase (EC 
2.7.1.78); D N A  polymerase (EC 2.7.7.7); type II site-specific DNase  
(EC 3 .1 .21 .4); proteinase K (EC 3.4.21,64); chondroitin ABC lyase (EC 
4 .1 2 .4 ) ;  D N A  ligase (EC 6.5.1.1).
gen types IV and VI(«2) [6- 8]. These interactions may increase 
the rigidity of the basement membrane and immobilize perlecan 
within the matrix. Up to date, little information is available re­
garding the functionality of the individual domains of the core 
protein. However, some insight into the roles of domain III and
I has been gained by previous in vitro expression studies. Do­
main III of mouse perlecan was produced by HT1080 cells [9]. 
The recombinant protein binds to the cell surface through in­
teraction of RGD peptide sequences with integrins [10]. Al­
though this tripeptide is not conserved in human perlecan an 
alternative cell binding mechanism may exist. In another study, 
domain III of human perlecan was expressed successfully in 
Escherichia coli. A monoclonal antibody was raised and used to 
demonstrate the ubiquity of perlecan in human basement mem­
branes [3]. Furthermore, expression of murine domain I in Chi­
nese hamster ovary cells provided evidence for the location of 
the glycosaminoglycan attachment sites near the N-terminus of 
perlecan [11].
The presence of the strongly anionic heparan sulfate is 
essential for the charge-selective permeability of the glomerular 
basement membrane [12]. Heparan sulfate has also been shown 
to bind a wide range of growth factors like heparin-binding epi­
dermal growth factor, inteiferon-y, granulocyte-macrophage col­
ony stimulating factor, interleukins IL-3, IL-8 and basic fibro­
blast-growth factor (bFGF) [13 — 16]. The biological activity of 
bFGF requires the presence of a specific oligosaccharide se~
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cjuence within heparan sulfate or heparin |14, 17). Binding to 
this oligosaccharide is essential for the growth factor to trigger 
its cell surface receptor. It was demonstrated that bFGF activa­
tion in vivo is solely dependent on the heparan sulfate chains ot 
perlecan [13].
Together with eell-surface heparan sulfate proteoglycans 
(HSPGs) of the vascular endothelium, perlecan also plays a role 
in the regulation of the coagulative response. Antithrombin III 
binding to heparan sulfate increases its anti-coagulant activity 
[18, 19]. Finally, perlecan may be involved in lipoprotein metab­
olism. Heparan sulfate chains are known to bind lipoprotein li­
pase, a key enzyme in lipoprotein metabolism [20, 21], Regard­
ing the strong similarity between domain II and the low-density 
lipoprotein receptor it cun be speculated that the heparan sulfate 
residues, lipoprotein lipase, low-density lipoprotein and domain
II might associate somehow into a large complex [22]. However, 
no experimental evidence has been obtained thus far to support 
this hypothesis. In the present study we have used recombinant 
baculovirus expression vectors (BEVs) to produce truncated per- 
iecan fragments that are both glycosylated and expressed at high 
level. The baculovirus expression system utilizes the extremely 
strong polyhedrin promoter by substituting the polyhedrin gene 
for a cDNA sequence encoding the protein of interest [23, 24]. 
Many post-translational modifications are well described in in­
sect cells, including O-glycosylation [25], N-glycosylation, pal- 
mitoylation and myristoylation. Although chondroitin sulfate 
and heparan sulfate proteoglycans have been observed in the 
fruit fly Drosophila melanogaster [26], no evidence is available 
yet for the correct synthesis of HSPGs during late stages of ba­
culovirus infection.
MATERIALS AND METHODS
Materials. Vent polymerase, T4 polynucleotide kinase, Xcml 
and Dralll endonuclease (New England Biolabs), BamHh Not], 
Pstl endonuclease, T4 DNA ligase, bFGF, methionine-deficient 
Grace’s medium, fetal bovine serum (Life Technologies), Srft 
endonuclease, pCR-Script plasmid (Stratagene Cloning Sys­
tems), pVL1393 plasmid (Invitrogen), Spodoptera frugiperda  
SF21 cells, wWd-typt Autographa calif arnica nuclear polyhedro- 
sis virus (AcNPV) strain C6, transfection reagent, BacPAK6 lin­
earized viral DNA (Clontech Laboratories), SDS-6B biotiny- 
lated marker, Brij35, TNM-FH insect culture medium (Sigma 
Chemical), RNAzol (Biotecx Laboratories), [35S]methionine 
(1CN Biomedicals), [}'-12P]ATP, Hybond N \  photographic film 
(Amersham), EN3HANCE (NEN), SDS (Fluka Chemie), Phast- 
System, FPLC system, MonoQ, Superose 12 column, DEAE- 
Sepharose CL-4B (Pharmacia Biotech), secondary antibody con- 
ju gates (Dakopatts), Immobilon-P membrane (Millipore), 
MultiMark prestained marker (Novex) and chondroitinase ABC 
from Proteus vulgaris (Seikagaku).
Construction of transfer vectors. Three transfer vectors 
were constructed designated pVL1393-Pl (encoding amino 
acids 1 — 196 of human perlecan), pVL!393-P12a (amino acids 
1—404) and pVL1393-P12ub (1—506). The initiation codon is
supplied by the insert; the open reading frame is placed out of 
the original polyhedrin reading frame to avoid aberrant initia­
tion. To introduce translation termination codons, mutagenic 
primers (Fig. 1) were used with clones Hpe2 and P5 [1] as tem­
plate and Vent polymerase. The PCR products were inserted into 
the Srfi cloning site of pCR-Script according to the suppliers 
protocol. Transformants (prepared according to [27]) were 
screened to contain the unique BamHl site at the 5' orientation 
and the N od  site at the 3' orientation from the cDNA fragments. 
The cDNA sequences were checked completely by sequencing
Product Nucleotides Primer set
1 41 -628 atggggtggcgggcgccgg (forward)
tcatgggaactggggcactgtgc (reverse)
2 543-1252 tcatctccagcggctctgt (forward)
ttftcatgcagccaaactcgtc (reverse)
3 985-1560 tgagctagactgtggccccc (forward)
icaggggcctgctcgttgtgg (reverse)
Fig, I. Primers used for introduction of translation stop codons into 
sequences of human perlecan. All sequences are in 5' to 3' direction; 
underlined residues indicates mismatch in mutagenic primer. Nucleotide 
numbering corresponds to the cDNA sequence available from GenBank 
by accession number X62515 [1].
(ABI apparatus type 37717). The BamHL-Notl fragment contain­
ing PCR product 1 (Fig. 1) was subcloned into pVL1393, 
yielding pVL1393-PL The X c m l-N o t l  fragment containing the 
major 3' part of PCR product 2 (Fig. 1) was subcloned into 
pVL1393-Pl, yielding pVL1393-P12il. The D r a l l l - N o t l  frag­
ment containing the major 3' part of PCR product 3 (Fig. 1) was 
subcloned into pVL1393-P12“, yielding pVL1393-P12“h.
Tissue culture and isolation of recombinant baculovi- 
ruses. The general tissue culture methods were adapted from 
[23]. Spodoptera fntgipercla SF21 cells were cultured at 27 °C in 
TNM-FH medium supplemented with 10% fetal bovine serum. 
Except where stated, monolayer cultures were used. Recombi­
nant viruses were derived from BacPAK6 by liposome-mediated 
cotransfection. The culture supernatant was harvested 4 days af­
ter cotransfection and individual plaques were obtained by a 
soft-agar overlay method. Well-isolated plaques were picked and 
left to diffuse overnight in 500 pi normal medium at 4°C. Pure 
plaques were propagated by infecting 5X10S SF21 cells in a 
35-inm dish with 100 \i\ of the plaque pick and harvesting the 
medium 4 days after infection. For further propagation of 
baculovirus strains during a maximum of two passages, suspen­
sion cultures of 50 ml were inoculated with 5X105 cells/ml and 
incubated until logarithmic growth. Cells were then infected 
with a multiplicity of 0.1 and harvested 96 h post-infection, at 
which time the cell densities had reached a plateau of about 
2X106 cells/ml. Cell densities were monitored in a hemocytome- 
ter (Blirker). Virus stocks were titrated by plaque assays. For 
expression of recombinant proteins, cells were infected at semi­
confluence with a multiplicity of 5 and harvested at 50 — 60 h 
post-infection.
Genomic analysis of BEVs. Independently isolated bacu­
lovirus strains were analyzed for correct integration locus and 
purity. Baculovirus genomic DNA was isolated from non-oc- 
cluded virions as described [28]. Shortly, the medium was 
cleared from cells (15 min at 300Xg) and non-occl tided virions 
were collected by ultracentrifugation for 1 h at 100000Xg. The 
virions were incubated overnight at 37 °C in presence of 0.1 mg/ 
ml proteinase K and 1 % SDS. The DNA was further purified 
following standard procedures [29] and stored at 4°C. After en­
donuclease Pstl digestion, 1 jig fragmented virus DNA was ap­
plied to each lane of a 0.35% agarose gel and separated over­
night at 4°C. Southern blot transfer to a Hybond N * membrane 
was performed overnight by capillary force. The filter was hy­
bridized at 42°C with an oligonucleotide (35 nucleotides) simi­
lar to exon 3 of human perlecan (domain I), and washed under 
medium stringent conditions (75 mM NaCl, 7.5 mM sodium 
citrate, 0.1 % SDS, pH 7.0 at 42°C). For autoradiography, a pho­
tographic film was developed after 4 days exposure.
[35S]Methionine incorporation and autoradiography. This 
procedure was adapted from [23]. A suspension culture of insect 
cells was grown to a cell density of 5X105 cells/ml and infected
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(PhastSystem). After blot transfer, recombinant proteins were detected 
with the niAb 95J10. Marker proteins are indicated on the left (SDS-6B 
bioiinylated marker and IV
r 'H  ^ jE on a 10-15% gradien gf>
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Fig, 5. Purification of the perkcan-(l-404)-peptide by size exclusion 
chromatogr
labeling with f;VS|rnethionine (lane I) was applied onto a Superuse 12
column under non-denaturirm conditions. Individual fractions (lanes 2 -
t  - i
9} were analyzed by 12.5 % SDS/PAGE and autoradiography. K ,, values 
are noted for each fraction. The arrow indicates the perleean-( i • 404)- 
peptide. Molecular mass markers are indicated on the right (MultiMark
marker).
respect ively ,  tak ing  r e m o v a l  o f  the s ignal  p e p t id e s  in to  a c c o u n t .  
To inves t iga te  the in tegr i ty  o f  the  tw o  p r o d u c e d  p ro te in s ,  i m m u ­
nologica l  s tud ies  w ere  p e r fo rm e d  w i th  the m A b  95.110 ( ra ised  
aga ins t  d o m a in  1 and  IF1 o f  h u m a n  per ieean  e x p r e s s e d  in E. coli) .
e r le c a iM  1 —4 0 4 ) -  an d  
~(1 —5 0 6 ) -p e p t id e  are im m u n o lo g ic a l ly  re la ted  to h u m a n  per- 
lecan (Fig. 4). As a con t ro l ,  the 9 5 J 10 e p i to p e  w as  no t  d e t e c t e d
ane  I ) o r  r e c o m -
:> L ' X i ^  r \  \ ani
s w e re  
w as
(data not shown).  The
iv*t 1 —5 mg
■ot:\
vs n
n ine - labe l led  s u p e rn a ta n t s  (Fig.  3, lane 3 a n d  4) w e r e  u sed  to 
in ves t iga te  the b e h a v io u r  o f  the per leca  n -(1 — 404')- a n d  -(1 —
on c h r o m a to g r a p h ic  meclia. For  s i z e - e x e lu s io n  
, a S u p e r o s e  12 c o lu m n  w a s  u t i l ized .  In d iv id u a l  
fract ions  were  co l lec ted  and  a l iquo ts  w ere  s e p a r a t e d  b y  S D S /
ins w ere  v i su a l i z e d  by a u t o r a d i o g r a p h y
(Fig. 5). Both  the p e r i e e a n -(1 —4 0 4 ) -  and  -(1 — 5 0 6 ) -p e p t id e  (not  
s h o w n )  e lu ted  at /v.iv. =  0 .23  — 0 .29 ,  w h e r e a s  these  b a n d s  d id  not
i n c ase o 11 he per  i e can  - (1 — 196)- pe p t ide o  r a f  te r i n fee t i o n
ata  not s
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Fig, 6. Anion-exchange chrom atography  of perleean-(l-404)-pep- 
['"S jiVIetliio niIïe-label led perlecan-(1 — 404) -peptide, purified by
size-cxclusion chromatography as shown in Fig, 5 (lane 2), was applied 
onto a M onoQ anion-exchange column. The protein strongly bound to 
the matrix at pH 6.8 and eluted in a linear NaCI gradient at a concentra­
tion of  0 .4 —0.5 M.
Fi g . 8. C h a r a cterization of g ly c os a ni i n o g I y c an s ex t ra  c t e d fro rn re - 
combi nan t per Iecan-(l-404)-pep tide. Lanes I and 4, marker glycosam- 
inoglycans (5 and 20 ng, respectively) heparan sulfate (HS), derm at an 
sulfate (DS) and chondroitin sulfate (CS); lanes 2 and 3, glycosarnino- 
giycans extracted from recombinant perlecan-( I • 
diluted and u ndi I u ted, res pec t i ve Iy). G ! ycosam i nog Iycans vvere s eparate d 
by agarose gel electrophoresis and stained with combined Azure A/silver
f -A  I
lí
r - iCh
L T
bilized bF G F ,  Increasing quantities of bFGF or BSA
Mis were
404)-peptide expressing cells, washed, and bound 
pepti d e w as trie a s u re d by E LIS A w ith rn A b 9 5 J 10.
- « i  i v . ate,, * ir°' “ 1 naui
s to imino-
were coated on
;rlecan-( 1 —
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
[NaCT| (M)
Fig. 7. Ion-exchange chrom atography  of intact and chondroitinase- 
ABC-digested pertecan-(1-404)-peptide. { • )  Intact perlecan-(l - 4 0 4 ) -  
peptide;  (O) pe r I ec a n - ('1 — 4(.)4) ~ pep tide digested with protease-free 
chondroitinase ABC, The proteins were eluted from DEAE-Sepharose 
beads using a stepwize NaCI gradient. .Aliquots of each fraction were 
analyzed in duplo  by an ELISA using the perlecan-specific mAb 95F10,
° ■‘crlecan-i I — 404)-peptide concentrations were measured as 
absorbance at 492 nm.
Amount coated Peptide bound to
BSA bFG F
ng
0 0.225 0.225
24 0.226 0.202
100 0.225 0.639
250 0.225 1.690
500 0.226 3.254
- h  ;p
Ï .
Table 2, Free glycosaminoglycans compete for binding of perlecan- 
(1-404)-peptide to bFGF. A constant amount of
coated on ELISA plates and binding of per lecan-(T-  
assayed in the presence of increasing concentrations ot 
fate (HS) or chondroitin sulfate (CS).
r .t
r / n
was 
^ a r a n  sul-
A n e ssenti a 11 y p lì re frac t i o n of  [ !3 S | m e th i o ni n c-d a be 11 e cl pe r- ( >() m t j t0 r c 0 nce n t rat on
/  a a à , » » % 9 i t  t  *  /  - r *  i r
i d :an-( 1 i  f  C i. 5, u
Competitor type
id by
2) was applied onto a M onoQ anion-exchange column to study 
its binding characteristics.  The  recombinant  protein strongly 
bound  to the matrix at pH 6.8. A linear salt gradient 
for elution and radioactivity o f  the fractions was qiu 
liquid scintillation counting (Fig. 6). The protein eluted from the 
n at a concentrat ion of  0 . 4 — 0.5 M NaCI.
•e was followed with ncm~n
its i ng i m m u n o 1 o s  ica! cletection
" 1  r \
; was
* sa i r* 1
cedures (Fig. 7). In this ease, the perlecan-( 1 -  
i nc u b a ted w i t h D E A E - S e p ha rose (a in a t ri x c a r ry i n g 
active groups as MonoQ).  After  elution with a NaCI gradient 
increasing stepwise from 0 to 1.0 M, all fractions were ant 
by an ELISA procedure  using 95J 10* Consistent  with the previ­
ous results, the majority of  the protein was detected in the frac­
tion containing 0.4 VI NaCI.
Characterization of glycosaminoglycan residues. The binding 
characteristics o f  the perleean-( 1 — 404)-peptide to anion-ex­
change beads suggest  that exposed negative charges are present 
on the molecule.  We therefore studied the s lycosvlat ion charac-
pg/ml
0 1.690 1.690
0,25 0,675 1.564
1 0.159 1.149
5 0.058 0.573
25 0,066 0.159
100 0.023 0.213
A B C  (protease-free),  its binding capacity to D E A E -Sepharose  
was abolished (Fig. 7) and the protein was found in the f low- 
through. F Ltrther evide nce tor  the presence of chondroi t in  s lt1 late 
residues on the recombinant  perlecan-(1 — 404)-pep 
in Fig. 8. Glycosaminoglycans  were extracted from the peri ec an- 
( I —404)-peptide by a 1 k a I i n e b o r o h y d r i de treatment an d it n a -
resis. A sinsle band was
comi grati nsto
agarose
teristics o f  the perlecan-(l  —4U4)-pepttae pt 
rus-infected insect cells. After treatment with chondroit inase
The above data suggest that the perleean-( 1 -  
produced by recombinant AcNPV, is glycosylated with one  or
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more chondroitin sulfate residues. The proteoglycan-like proper­
ties oi the perlecan-( 1 —404)-peptide conform with its ability to 
bind bFGF (Table 1). This was demonstrated by coating increas­
ing quantities of bFGF on ELISA plates, incubating with culture 
supernatant of bacuJovirus-infected insect cells, and determining 
the amount of immobilized perlecan-( 1 — 404)-peptide in an 
ELLSA-Iike procedure with mAb 95J 10. This interaction be­
tween the perlecan-0 —404)-peptide and bFGF is inhibited in 
the presence of free glycosaminoglyeans, heparan sulfate being 
a stronger competitor than chondroilin sulfate (Table 2). This is 
not surprising since bFGF has been reported to have a higher 
affinity for heparan sulfate than for chondroitin sulfate. The re­
sults indicate that the binding of the perlecan-(l —404)-peptide 
to immobilized bFGF is mediated by the glycosaminoglycan 
moieties of the recombinant proteoglycan.
DISCUSSION
No recombinant protein is synthesized by BEVs encoding the 
perlecan-(l-196)-peptide. The inability of AcNPV-infected in­
sect cells to produce the recombinant perlecan-(l — 196)-peptide 
is poorly understood. The possibility of a frame shift or point 
mutation in the cDNA construct was excluded by sequence 
analysis. Baculoviruses carrying the cDNA construct encoding 
the perleean-(l — '196)-peptide were convincingly shown to con­
tain the insert correctly in the polyhedrin locus, and the size of 
the cDNA fragment was confirmed by PCR. These results 
clearly indicate that the recombinant virus offers an intact open 
reading frame. Transcriptional analysis by northern blotting 
showed that an unexpectedly long mRNA (approx. 4 kb) was 
present, induced between 12 — 36 h post-infection. However, no 
recombinant protein was produced.
One possible explanation for the deficiency in recombinant 
pcrlecan-(l — 196)-peptide production is the inefficient use of the 
polyadenylation signal. In late phases of baculovirus infection, 
transcription is mediated by a virus-encoded RNA polymerase 
[35J and not all factors that influence termination of transcrip­
tion by this enzyme are known [36]. For the AcNPV polyhedrin 
gene, multiple transcripts (1.2, 3.4 and 4.9 kb in size) have been 
observed with a common 5' end [37, 38]. Therefore the elon­
gated mRNA might result from read-through transcription, and 
we speculate that this may cause instability of the mRNA.
Another reason for the lack of perlecart-(l~196)-peptide ex­
pression could be the activity of an additional late-phase pro­
moter positioned approximately 2 kb downstream of the polyhe­
drin coding sequence [37]. This promoter drives the transcrip­
tion of a 3.2-kb mRNA in the opposite orientation, comprising 
the anti sense strand of the inserted cDNA. Since the probe used 
for northern hybridization was double-stranded, the observed 
signal may represent the antisense transcript, in wild-type 
AcNPV, the level of this transcript is down-regulated by tran­
scription from the polyhedrin promoter [37]. Possibly the con­
sensus generated in this BEV influences the balance between 
sense and antisense transcription, in favour of the antisense 
product.
Successful expression and purification of perIecan-(l-404)- 
and -(l-506)~peptide. The recombinant perlecan-(l —404)- 
and -(1 ~5Q6)-peptide, comprising domains I and II of human 
perlecan, were successfully synthesized in the baculovirus ex­
pression system. This was shown by metabolic labeling (Fig. 3) 
and immunological assays with the mAb 95J10 (Fig. 4). The 
signal peptide (originating from human perlecan cDNA) was 
recognized and the proteins were transported to the extracellular 
compartment. During electrophoresis on a 12.5% SDS/poly­
acrylamide gel, the |-S(methionine-labelled recombinant pro­
teins migrate as 53-kDa and 62-kDa proteins, respectively, 
which is IGkDa larger than the calculated mass of their core 
proteins. As argued below, this difference can be explained by 
post-translational modifications, since the electrophoretic mobil­
ity of glycosylated proteins does not correlate to molecular mass 
in a linear logarithmic manner. In contrast, elution on a gel per­
meation column calibrated with globular marker proteins takes 
place at -  0.23-0.26 which coincides with an apparent 
mass of 180-250 kDa. This discrepancy illustrates that molecu­
lar mass determinations based on relative mobility should be 
considered very carefully, especially when proteoglycans are in­
volved. The yield of between 1-5 mg recombinant protein/10” 
cells is in agreement with the results obtained with other recom­
binant proteins [23).
Identification of glycosaminoglycans as chondroitin sulfate.
The presence of chondroitin sulfate glycosaminoglycans on ba~ 
culovirus-derived perlecan-(l -404)-peptide is supported by the 
following findings. Firstly, the perlecan-(l -404)-peptide strongly 
binds to the anion-exchange matrices DEAE-Sepharose CL-4B 
and MonoQ. The observed elution pattern resembles the charac­
teristic behaviour of proteoglycans previously isolated from 
basement membranes [39, 40]. Secondly, the binding capacity 
of the perlecan-(l —404)-peptide to anion-exchange columns is 
abolished by chondroitinase ABC treatment. Furthermore, gly­
cosaminoglycans isolated from the perlecan-(l — 4Q4)-peptide 
were convincingly identified as chondroitin sulfate (Fig. 8) by 
agarose gel electrophoresis. Finally, the perlecan~(l —404)-pep- 
tide binds to immobilized bFGF (Table 1). This interaction is 
inhibited in presence of free glycosaminoglycans (Table 2), sug­
gesting that binding of the perlecan-(l-404)-peptide is medi­
ated through its side chains.
Although the interaction between bFGF and the perlecan- 
(1 —404)-peptide provides evidence for attachment of glycosam­
inoglycans, it can hardly be compared to the binding event that 
occurs in the basement membrane. The binding of bFGF in vivo 
is known to require specific oligosaccharide sequences that are 
present solely in heparan sulfate and heparin [13, 41 j, involving 
a dissociation constant of 10~*-10~,J M [16]. In our ELISA- 
based binding assay the affinity must be lower, since free chon­
droitin sulfate acts as a potent competitor. We therefore conclude 
that baculovirus-derived perlecan-(l —404)-peptide binds to im­
mobilized bFGF with relatively low affinity through its chon­
droitin sulfate chains.
The appearance of chondroitin sulfate residues on the per- 
lecan-(l —404)-peptide is unexpected since the predominant in 
vivo form of perlecan carries heparan sulfate chains. Some ef­
forts have been made to elucidate the factors influencing glyco- 
sylation of proteoglycans. The composition of glycosaminogly­
can chains has been found to depend firstly on the amino acid 
sequence of the core protein [42]. The primary structure of per­
lecan domain i permits both attachment of heparan sulfate and 
chondroitin sulfate [11], A second determinant for glycosylation 
is the cell type in which the proteoglycan is synthesized. Hybrid 
heparan/chondroitin sulfate forms of perlecan have been ob­
served in Engelbreth-Holm-Swarm tumor cells [43], in cultured 
human glomerular visceral epithelial cells [44] and Chinese 
hamster ovary cells [11]. It is therefore comprehensible that the 
perlecan-(1 —404)-peptide is expressed as a chondroitin sulfate 
proteoglycan. However, the exact determinants for this type of 
glycosylation remain unclear.
Application of recombinant fragments of human perlecan.
Expression of perlecan fragments in the baculovirus system pro­
vides an important tool to study the functions of this proteogly­
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can in a domain-specific manner. In the present study we de­
scribed the expression and purification of perlecan-(l-404)- 
and -(1 -506)-peptide, comprising the two N-terminal domains 
of perieean. Given the spatial separation of the structural do­
mains as visualised by electron microscopy [45], it is likely that 
the perlecan-i 1 —506)-peptide will have identical properties as 
the corresponding globulus in the whole perlecan molecule. The 
included domains are likely candidates to play a role in lipopro­
tein metabolism. Domain II of perlecan shows strong similarity 
with the ligand binding domain of the low-density lipoprotein 
receptor [1, 2|. A synergic action has been proposed for the 
combined binding of lipoprotein together with lipoprotein lipase, 
a complex that could be stabilized by a favourable configuration 
of heparan sulfate in the proximity of the low-density lipoprotein 
receptor-like domain [20, 22]. These and other hypothetical 
functions of the N-terminal core domains of perlecan will be 
assessed in the future.
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